Search Results - "Bose, Chinmoy"

Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer by Bose, Chinmoy K.

“…Recurrent and metastatic cervical cancer is generally treated by cisplatin, paclitaxel, and bevacizumab with limited benefit this constituting an unmet need…”
Get full text

Controversy of tissue-agnostic approvals in immunotherapy and targeted therapy by Bose, Chinmoy K.

“…In recent years, approval of some immunotherapy based on markers such as dMMR, tumour mutational burden and other few such markers is not received well as…”
Get full text

Bispecific immunotherapy MEDI5752 or volrustomig and cervical cancer by Bose, Chinmoy K, Basu, Nirban

“…MEDI5752 is a monovalent bispecific immunotherapy and is strategically unique as it combines both anti programmed cell death 1 and anti cytotoxic…”
Get full text

Combined positive score (CPS) for scoring PD-L1 positivity by Bose, Chinmoy, Mukhopadhyay, Soma

Get full text

Immune Checkpoint Blockers and Ovarian Cancer by Bose, Chinmoy K

“…Abstract Although the idea, called “cancer immunotherapy,” is very appealing and has previously been shown to work in several mouse models of cancer, it has in…”
Get full text

Debating cancer: The paradox in cancer research by Mukhopadhyay, Ashis, Bose, Chinmoy

“…The basis for the gene mutation theory of cancer that dominates current molecular cancer research consists of the belief that gene-level aberrations such as…”
Get full text

Immune checkpoints, their control by immunotherapy and ovarian cancer by Bose, Chinmoy K

“…Immune checkpoints are new targets for manipulation of immunological control over malignant tumors. They provide an important means to manage especially…”
Get full text

Anomalous endocrine feedback of peri-menopause in the etiology of type II ovarian cancer by Bose, Chinmoy K

Get more information

Follicle stimulating hormone receptor in ovarian surface epithelium and epithelial ovarian cancer by Bose, Chinmoy K

“…Epithelial ovarian cancer (EOC) has remained an enigmatic disease, the etiology of which is mostly unknown. Considering the age incidence around menopause, a…”
Get more information

Cancer screening for women in developing countries by Bose, Chinmoy K

Get full text

Inhibitory role of a smart nano-trifattyglyceride of Moringa oleifera root in epithelial ovarian cancer, through attenuation of FSHR - c-Myc axis by Ghosh, Arijit, Roychowdhury, Tanaya, Nandi, Rajesh, Maiti, Rituparna, Ghosh, Narendra N., Molla, Sabir A., Mukhopadhyay, Soma, Prodhan, Chandraday, Chaudhury, Keya, Das, Priyabrata, Sarkar, Nirmal K., Chattopadhyay, Samit, Bhattacharya, Rittwika, Bose, Chinmoy K., Maiti, Dilip K.

“…Background and aim: Epithelial ovarian cancer has the deadliest prognosis amongst gynaecological cancers, warranting an unmet need for newer drug targets…”
Get full text

Tender human mind by Bose, Chinmoy K, Dr

Get full text

Determinants of lymph node status in women with breast cancer: A hospital based study from eastern India by Chakraborty, Abhijit, Bose, Chinmoy, Basak, Jayasri, Sen, Aditya, Mishra, Raghwendra, Mukhopadhyay, Ashis

“…Background & objectives: Number of metastatic lymph nodes has a strong prognostic value in the course of breast cancer treatment, morbidity and mortality. This…”
Get full text

Emil "Tom" Frei III, MD (1924-2013) by Bose, Chinmoy K.

“…First is, a bacteriologist, poet and author of several books Dr. Hans Zinsser. [...]they established Emil Frei Art Glass Company there. "Dr.\n Dr. Frei's point…”
Get full text

Is randomized trial of neoadjuvant chemotherapy of ovarian cancer necessary? by Bose, Chinmoy K

Get full text

PARP inhibitors and more by Bose, Chinmoy K., Basu, Nirban

“…Polyadenosine diphosphate (ADP) ribose polymerase (PARP) lends a panoramic view to the inner mystery of protection of integrity of deoxyribonucleic acid (DNA)…”
Get full text

Hyponatremia of non-small cell lung cancer: Indian experience by Bose, Chinmoy K, Dey, Subhashis, Mukhopadhyay, Ashis

“…Abstract Background: Hyponatremia is a hazardous complication of lung cancer and its treatment. It is seen at presentation in approximately 15% of patients…”
Get full text

Cancer survival in high-income and low-income countries: role of dose calculation of chemotherapy by Bose, Chinmoy K

Get full text

Yang,C.Q., Chan,K.Y.K., Ngan,H.Y.S., Khoo,U.S., Chiu,P.M., Chan,Q.K.Y., Xue,W.C., and Cheung,A.N.Y. Single nucleotide polymorphisms of follicle-stimulating hormone receptor are associated with ovarian cancer susceptibility. Carcinogenesis, July 2006; 27, 1502–1506 by Bose, Chinmoy K.

Get full text

Follicle stimulating hormone receptor (FSHR) antagonist and epithelial ovarian cancer (EOC) by Bose, Chinmoy K

“…Follicle stimulating hormone receptor (FSHR), a G-protein coupled receptor present in granulosa cell of ovary is a unique transmembrane molecule pivotal in…”
Get more information